ImmuCell Stock

ImmuCell EBITDA per Employee

The EBITDA per Employee of ImmuCell (ICCC) as of Aug 5, 2026 is 30,542.69 USD. In the previous year, EBITDA per Employee was -30,658.33 USD — a change of -199.62% (higher).

EBITDA per Employee

30,542.69USD

YoY

-199.62%

Last updated:

EBITDA per Employee of ImmuCell is 2026 30,542.69 USD. EBITDA per Employee of ImmuCell was 2025 -30,658.33 USD. It decreases by -199.62% higher compared to the previous year.
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

EBITDA per Employee of ImmuCell is 30,542.69 USD in 2026.

EBITDA per Employee of ImmuCell changed from -30,658.33 USD to 30,542.69 USD, representing a -199.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee ImmuCell since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's ImmuCell historically and in real time.

Access this data via the Eulerpool API

Workforce — ImmuCell

All Key Metrics — ImmuCell